NZ Multiple Myeloma Research Review Issue 29

In this issue:

Real-life safety and efficacy of autologous SCT in elderly MM
Early access daratumumab for relapsed/refractory MM in the US
VTE in relapsed/refractory MM treated with lenalidomide + dexamethasone
Real-world carfilzomib and other systemic MM regimens in the US
Lenalidomide maintenance vs. observation for newly diagnosed MM
Adding daratumumab to bortezomib and dexamethasone in relapsed/refractory MM
BH3-mimetic toolkit guides BCL2 and MCL1 BH3-mimetic use in myeloma
Subclonal TP53 copy number is associated with MM prognosis
MRD negativity is a major prognostic factor in MM

Please login below to download this issue (PDF)

Subscribe